Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Pacira BioSciences (Nasdaq: PCRX) will participate in analyst-led fireside chats at two upcoming healthcare conferences: the Jefferies London Healthcare Conference on Nov 18, 2025 at 1:30 PM GMT (8:30 AM ET) and the 37th Annual Piper Sandler Healthcare Conference on Dec 2, 2025 at 1:30 PM ET.
Live audio of both events will be available on the company’s Events page at investor.pacira.com, and webcasts will be replayable for two weeks after each event.
Details
News Market Reaction – PCRX
On Nov 11, the day this news came out, PCRX closed 4.55% above the previous close.
Data tracked by StockTitan Argus for the Nov 11 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BRISBANE, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will participate in an analyst-led fireside chat at the following two healthcare conferences:
- Jefferies London Healthcare Conference on Tuesday, November 18th at 1:30PM GMT (8:30AM ET).
- 37th Annual Piper Sandler Healthcare Conference on Tuesday, December 2nd at 1:30PM ET.
Live audio of the events can be accessed by visiting the “Events” page of the company’s website at investor.pacira.com. A replay of the webcasts will also be available for two weeks following the events.
About Pacira
Pacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and ioveraº®, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The company is also advancing the development of PCRX-201 (enekinragene inzadenovec), a novel locally administered gene therapy with the potential to treat large prevalent diseases like osteoarthritis. To learn more about Pacira, visit www.pacira.com.
Company Contact: Pacira BioSciences, Inc. Christian Pedetti (973) 254-4387 Christian.pedetti@pacira.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.